Medicine and Dentistry
Nilotinib
100%
Combination Therapy
62%
Patient
62%
Heart Left Ventricle Ejection Fraction
37%
Adverse Event
37%
QT Interval
37%
Follow up
25%
Inpatient
25%
Therapeutic Procedure
25%
Measurement
12%
Coronary Artery Disease
12%
Heart Function
12%
Cardiovascular Risk
12%
Imatinib
12%
Chronic Myelogenous Leukemia
12%
Cardiovascular System
12%
Tyrosine-Kinase Inhibitor
12%
ECG Abnormality
12%
QT Prolongation
12%
Life
12%
Monitoring
12%
INIS
patients
87%
therapy
62%
range
50%
risks
25%
information
25%
safety
25%
design
12%
monitoring
12%
clinical trials
12%
diseases
12%
management
12%
kinases
12%
values
12%
tyrosine
12%
myeloid leukemia
12%
coronaries
12%
arteries
12%
Pharmacology, Toxicology and Pharmaceutical Science
Nilotinib
100%
Adverse Event
37%
Clinical Trial
25%
Cardiovascular Risk
12%
Coronary Artery Disease
12%
ECG Abnormality
12%
Chronic Myeloid Leukemia
12%
Imatinib
12%
Protein Tyrosine Kinase Inhibitor
12%
QT Prolongation
12%